PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045096 / 12118430 Report Date : 27/Feb/2025 04:20PM
Referred By : Dr. Report Status : Final Report
Sample Type : Whole Blood-EDTA

HAEMATOLOGY
Test Name Result Unit Bio. Ref. Interval Method

Complete Blood Count

Hemoglobin 13 g/dL 13.0-17.0 Cyanide Free SLS
RBC 4.06 10^6/[Link] 4.5 - 5.5 Impedance
HCT 39.6 % 40 - 50 Calculated
MCV 97.4 fL 83 - 101 RBC pulse measurement
MCH 31.9 pg 27 - 32 Calculated
MCHC 32.7 g/dL 31.5 - 34.5 Calculated
RDW-CV 16.7 % 11.6-14 Calculated
Total Leucocyte Count 5.40 10^3/µL 4 - 10 Impedance
Differential Leucocyte Count
Neutrophils 45.7 % 40-80 DHSS/Microscopy
Lymphocytes 43.4 % 20-40 DHSS/Microscopy
Monocytes 9.4 % 2-10 DHSS/Microscopy
Eosinophils 1.3 % 1-6 DHSS/Microscopy
Basophils 0.2 % 0-2 Impedance/Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 2.47 10^3/µL 2-7 Calculated
Absolute Lymphocyte Count 2.34 10^3/µL 1-3 Calculated
Absolute Monocyte Count 0.51 10^3/µL 0.2 - 1 Calculated
Absolute Eosinophil Count 0.07 10^3/µL 0.02 - 0.5 Calculated
Absolute Basophil Count 0.01 10^3/µL 0.02-0.1 Calculated
Platelet Count 177 10^3/µL 150-410 Impedance /Microscopy
MPV 9.8 fL 6.5 - 12 Calculated
PDW 15.7 fL 9-17 Calculated

Comment:
As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are
additionally being reported as absolute numbers of each cell in per unit volume of blood.
DHSS : Double Hydrodynamic Sequential System

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 1 of 11
 PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045096 / 12118430 Report Date : 27/Feb/2025 03:27PM
Referred By : Dr. Report Status : Final Report
Sample Type : WHOLE BLOOD-EDTA

HAEMATOLOGY
Test Name Result Unit Bio. Ref. Interval Method

HbA1c (Glycosylated Hemoglobin)

Glycosylated Hemoglobin (HbA1c) 4.8 % 4 - 5.6 HPLC (NGSP certified)
Estimated average glucose (eAG) 91.06 mg/dL Calculated

Comment:
Interpretation: HbA1c%

≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes

Adapted from American Diabetes Association.

Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.

Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.

• HPLC - High performance liquid chromatography

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 2 of 11
 PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045095 / 12118430 Report Date : 27/Feb/2025 03:27PM
Referred By : Dr. Report Status : Final Report
Sample Type : Fluoride Plasma F

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

FBS (Fasting Blood Sugar)

Glucose - Fasting 74 mg/dL 70-99 Hexokinase/G-6-PDH

Fasting Plasma Glucose (mg/dL) 2 hr plasma Glucose (mg/dL) Diagnosis

99 or below 139 or below Normal
100 to 125 140 to 199 Pre-Diabetes (IGT)
126 or above 200 or above Diabetes

Reference : American Diabetes Association

Comment:
Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not
have it yet. A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour
glucose level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes

Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
Less than 7%
HbA1c

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 3 of 11
PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045097 / 12118430 Report Date : 27/Feb/2025 03:43PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

Lipid Profile
Cholesterol - Total 98 mg/dL Low (desirable): < 200 Enzymatic
Moderate (borderline)
200–239
High: >/= 240
Triglycerides 61 mg/dL Normal: <150, GPO
Borderline: 150 - 199,
High:200-499,
Very High>=500
Cholesterol - HDL 39 mg/dL Undesirable/high risk <40 Accelerator Selective
Desirable/low risk>=60 Detergent
Cholesterol - LDL 47 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 12 mg/dl <30 Calculated
Cholesterol : HDL Cholesterol 2.5 Ratio Desirable : 3.5-4.5 Calculated
High Risk : >5
LDL : HDL Cholesterol 1.20 Ratio Desirable : 2.5-3.0 Calculated
High risk : >3.5
Non HDL Cholesterol 59 mg/dl Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220

Comment:

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 4 of 11
PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045097 / 12118430 Report Date : 27/Feb/2025 03:43PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-

Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC

New treatment goals by Lipid Association of India (2020)

CONSIDER THERAPY (cut-off level) TREATMENT GOALS
Risk groups LDL-C (mg/dL) Non-HDLC (mg/dL) LDL-C (mg/dL) Non-HDLC (mg/dL)
<50 <80
Extreme Risk Gp Cat. A ≥50 ≥80
(Optional ≤30) (Optional ≤60)
Extreme Risk Gp Cat. B >30 >60 ≤30 ≤60
Very High Risk ≥50 ≥80 <50 <80
High Risk ≥70 ≥100 <70 <100
Moderate Risk ≥100 ≥130 <100 <130
Low risk ≥130* ≥160* <100 <130
*After an adequate non-pharmacological intervention for at least 3 months

•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 5 of 11
 PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045097 / 12118430 Report Date : 27/Feb/2025 03:43PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.

Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.

LIVER FUNCTION TEST

Liver Function Test
Bilirubin-Total 0.68 mg/dL 0.3 – 1.2 Vanadate oxidation
Bilirubin-Direct 0.30 mg/dL 0.0-0.3 Vanadate oxidation
Bilirubin-Indirect 0.38 mg/dL 0.2-0.8 Calculated
Protein, Total 6.20 g/dL 5.7–8.2 Biuret
Albumin 3.90 g/dL 3.2-4.8 BCG Dye Binding
Globulin 2.3 g/dl 2.1 - 3.9 Calculated
A/G Ratio 1.70 Ratio 0.8 - 2.1 Calculated
Aspartate Transaminase (SGOT) 38 U/L <34 Modified IFCC
SGPT (Alanine Transaminase) 46 U/L 10-49 Modified IFCC
SGOT/SGPT 0.83 Ratio Calculated
Alkaline Phosphatase 86 U/L 46-116 IFCC Standardization
Gamma Glutamyltransferase (GGT) 41 U/L <73 Modified IFCC

Comment:

Raised ALT and AST indicate hepatocellular damage (e.g. viral or drugs etc). ALT is more liver-specific while AST is also
found in heart, skeletal muscle, and kidney. Mild elevation (less than twice normal) often resolves on its own. Fatty liver
disease (especially with metabolic syndrome) is a common cause in asymptomatic cases. Certain drugs (paracetamol,
statins), herbal supplements, energy drinks, and antibiotics may also affect liver function.
SGOT/SGPT Ratio: Typically <1 in healthy individuals (vary between 0.7-1.4; higher in women than men). High SGPT (ratio
<1) seen in acute or chronic hepatitis, autoimmune disorders, medications, toxins while ratio >1 indicates alcoholic
hepatitis, cirrhosis, metastasis or non-hepatic issues (hemolytic diseases, CVS disorders).
Elevated Alkaline Phosphatase and GGT: Suggest cholestatic diseases (e.g. bile duct obstruction, primary biliary
cirrhosis etc.) and can also be due to bone disease, pregnancy, chronic renal failure, malignancy, and congestive heart
failure.
High Bilirubin: Indicates jaundice due to increased RBC breakdown, liver damage (e.g., infections, toxins), or cholestasis

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 6 of 11
PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045097 / 12118430 Report Date : 27/Feb/2025 03:43PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
(e.g., gallstones, tumors).
High Protein Levels: Seen in dehydration (e.g., severe vomiting, diarrhea) or increased production (e.g., inflammation,
hematopoietic neoplasms). Low protein and albumin: Result from impaired synthesis (liver disease), decreased intake,
tissue damage, malabsorption, or increased renal excretion.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 7 of 11
 PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045097 / 12118430 Report Date : 27/Feb/2025 03:44PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

Urea
Urea 19.26 mg/dL 19.26-49.22 Calculated

Comment:

Elevated Blood Urea can occur with kidney disease, but it can also happen from high protein diet, increased protein
breakdown, certain medications, dehydration or burns, GI haemorrhage, cortisol and renal failure. Blood urea levels often
rise with aging as well.
Abnormally low levels of Blood Urea can be a sign of malnutrition, lack of protein in the diet, and liver disease.

Note:

Independently, blood urea may not reflect kidney function. For this reason, it is often interpreted in the context of other
measurements, such as creatinine, a breakdown product of the muscle, that is filtered by the kidneys.
In blood, Urea is usually reported as BUN and expressed in mg/dl. BUN mass units can be converted to urea mass units by
multiplying by 2.14.

Creatinine
Creatinine 1.00 mg/dL 0.7-1.3 Alkaline picrate-kinetic

Comment:

Creatinine is a more specific and sensitive indicator of renal disease than Blood Urea Nitrogen.

Uses:

To diagnose renal insufficiency;

Adjusting dosage of renally excreted medications.
Monitoring renal transplant recipients.
Serum creatinine levels are a proxy for reduced skeletal muscle mass.
Serum creatinine measurement is used in estimating the Glomerular Filtration Rate (GFR) for people with Chronic Kidney
disease (CKD) and those with risk factors for CKD (Diabetes Mellitus, hypertension, cardiovascular disease, and family
history of kidney disease).

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 8 of 11
 PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045097 / 12118430 Report Date : 27/Feb/2025 03:44PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

Increased In: Blockage in the urinary tract, Pre- and postrenal azotemia, Impaired kidney function, Loss of body fluid
(dehydration), Muscle diseases such as gigantism, acromegaly.
Decreased In: Pregnancy, certain drugs (e.g., cimetidine, trimethoprim), Myasthenia Gravis, Muscular dystrophy.

Uric Acid
Uric Acid 5.6 mg/dL 3.5-7.2 Uricase/Peroxidase

Comment:

Uric acid levels show diurnal variation. The level is usually higher in the morning and lower in the evening. Increased levels
are seen in starvation, strenuous exercise, malnutrition, or lead poisoning, gout, renal disorders, increased breakdown of
body cells in some cancers (including leukemia, lymphoma, and multiple myeloma) or cancer treatments, hemolytic anemia,
sickle cell anemia, or heart failure, pre-eclampsia, liver disease (cirrhosis), obesity, psoriasis, hypothyroidism, low blood
levels of parathyroid hormone (PTH), certain drugs, foods that are very high in purines - such as organ meats, red meats,
some seafood and beer. Decreased levels are seen in liver disease, Wilson's disease, Syndrome of inappropriate
antidiuretic hormone (SIADH), certain drugs.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 9 of 11
 PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045098 / 12118430 Report Date : 27/Feb/2025 05:30PM
Referred By : Dr. Report Status : Final Report
Sample Type : Urine

CLINICAL PATHOLOGY
Test Name Result Unit Bio. Ref. Interval Method

Urine Routine & Microscopy

Urine Routine & Microscopy
Colour Pale Yellow Pale Yellow
Appearance Clear Clear
Specific gravity 1.030 1.003 - 1.035 pKa change
pH 6.0 4.6 - 8.0 Double Indicator
Glucose Negative Negative GOD-POD
Protein Trace Negative Protein Error Principle
Ketones Negative Negative Nitroprusside
Blood Negative Negative Peroxidase
Bilirubin Negative Negative Diazonium
Urobilinogen Normal Normal Ehrlich
Leucocyte Esterase Negative Negative Pyrrole
Nitrite Negative Negative P-arsanilic acid
Pus cells 1-2 /hpf 0-5 Microscopy
Red Blood Cells Nil /hpf 0-2 Microscopy
Epithelial cells 1-2 /hpf Few Microscopy
Casts Nil /lpf Nil Microscopy
Crystals Nil Nil Microscopy
Yeast Nil Nil Microscopy
Bacteria Nil Nil Microscopy

Comment:
•Note: Pre-test condition to be observed while submitting the sample-first void, mid stream urine, collected in a clean, dry, sterile
container is recommended for routine urine analysis, avoid contamination with any discharge from vaginal, urethra, perineum,
Avoid prolonged transit time & undue exposure to sunlight.
•During interpretation, points to be considered are Negative nitrite test does not exclude the urinary tract infections. Trace
proteinuria can be seen with many physiological conditions like prolonged recumbency, exercise, high protein diet. False positive
reactions for bile pigments, proteins, glucose and nitrites can be caused by peroxidase like activity by disinfectants, therapeutic
dyes, ascorbic acid and certain drugs.• Urine microscopy is done in centrifuged urine specimens

*** End Of Report ***

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 10 of 11
 PO No :PO4152597804-856

Name : [Link] SINGH Client Name : TATA 1MG OKHLA

Age/Gender : 22/Male Registration Date : 27/Feb/2025 11:35AM
Patient ID : OKH1978714 Collection Date : 27/Feb/2025 09:08AM
Barcode ID/Order ID : D16045098 / 12118430 Report Date : 27/Feb/2025 05:30PM
Referred By : Dr. Report Status : Final Report
Sample Type : Urine

CLINICAL PATHOLOGY
Test Name Result Unit Bio. Ref. Interval Method
Conditions of Laboratory Testing & Reporting:
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID care@[Link]

Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 11 of 11
 Name : [Link] SINGH Client Name : TATA 1MG OKHLA
Age/Gender : 22 Y 0 M 0 D /Male Registration Date : 28/Feb/2025 02:41PM
Patient ID : OKH1981580 Collection Date : 28/Feb/2025 11:09AM
Barcode ID/Order ID : A17070817 / 12119763 Report Date : 28/Feb/2025 05:12PM
Referred By : SELF Report Status : Final Report
Sample Type : Fluoride Plasma P

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

PPBS (Postprandial Blood Sugar)

Glucose Postprandial 92 mg/dL 70 - 140 Hexokinase/G-6-PDH

Comment:
Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not
have it yet. A level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour
glucose level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.

Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
HbA1c Less than 7%

*** End Of Report ***

Conditions of Laboratory Testing & Reporting:
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID care@[Link]

Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 1 of 1
 Print Date 27/02/2025 [Link]

X-RAY CHEST PA VIEW

Bony thoracic cage, extra pulmonary soft tissue and domes of diaphragm are normal.

Clinical correlation would be necessary

DISCLAIMER : THIS IS A PROFESSIONAL OPINION AND NOT A DIAGNOSIS. THE SCIENCE OF RADIOLOGY IS BASED UPON INTERPRETATIONS OF
RADIOLOGICAL IMAGES OF NORMAL & ABNORMAL TISSUES; THIS IS NEITHER COMPLETE NOR ACCURATE HENCE THE FINDINGS SHOULD ALWAYS BE
INTERPRETED IN THE LIGHT OF CLINICO PATHOLOGICAL [Link] INTIMATE US FOR ANY TYPING MISTAKES AND SEND THE REPORT FOR
CORRECTION.

DR. IBETHOI YENGKHOM DR. RAJAT SACHDEVA DR. ARTI GROVER MEHTA
MBBS, MD. (RADIODIAGNOSIS) MBBS, MD (RADIO-DIAGNOSIS)MBBS MD RADIO-DIAGNOSIS
ASC. PROFESSOR & SENIOR RADIOLOGIST
D.M.R.D, D.N.B, F.R.C.R
DMC 54223 NMC-13590
UPMC 104186
Page No: 1 of 2